Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.

Don S. Dizon Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI info_outline Don S. Dizon, Cara Amanda Mathews, Shannon MacLaughlan David, Jason T Machan, Matthew James Hadfield, Eric I Marks, Rani Bansal, Christine McGinn, Faith Hassinger, Denise Luppe, Janine Grigelevich, Kelly A Mitchell, Adam Braga, Ashlee Sturtevant, Roxanne Wood, Ursula A. Matulonis, Alexi A. Wright, Susana M. Campos, Michael J. Birrer

Authors Don S. Dizon Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI info_outline Don S. Dizon, Cara Amanda Mathews, Shannon MacLaughlan David, Jason T Machan, Matthew James Hadfield, Eric I Marks, Rani Bansal, Christine McGinn, Faith Hassinger, Denise Luppe, Janine Grigelevich, Kelly A Mitchell, Adam Braga, Ashlee Sturtevant, Roxanne Wood, Ursula A. Matulonis, Alexi A. Wright, Susana M. Campos, Michael J. Birrer Organizations Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, Women and Infants Hospital, Providence, RI, University of Illinois at Chicago, Chicago, IL, Rhode Island Hospital/Alpert Medical School of Brown University, Providence, RI, Rhode Island Hospital, Brown University, Providence, RI, Boston University Medical Campus, Boston, MA, Duke Cancer Institute, Durham, NC, Lifespan Cancer Institute, Providence, RI, Lifespan, Providence, RI, Brown University Oncology Research Group, Providence, RI, Dana-Farber Cancer Institute, Boston, MA, University of Arkansas for Medical Sciences, Little Rock, AR Abstract Disclosures

Clinical